RIO DE JANEIRO, Nov 9 (Reuters) – Brazil’s well being regulator mentioned on Monday it had suspended scientific trials for China’s Sinovac coronavirus vaccine, resulting from a “extreme antagonistic impact” that occurred on Oct. 29 however didn’t instantly present additional particulars.
Sao Paulo’s medical analysis institute Butantan, which is conducting the Sinovac trials in Brazil, mentioned it “was stunned” by the choice and would maintain a information convention on Tuesday at 11 a.m. native time (1400 GMT).
The well being regulator, Anvisa, didn’t specify whether or not the incident occurred in Brazil – the place trials are being performed – or out of the country. It additionally didn’t say why information of the October occasion was being communicated solely now.
Sinovac didn’t instantly reply to requests for remark.
No different nation conducting trials of Sinovac’s experimental vaccine has introduced a suspension. Late-stage trials are additionally being performed in Indonesia and Turkey.
Sinovac’s vaccine is among the many three experimental COVID-19 vaccines that China has been utilizing to inoculate a whole bunch of hundreds of individuals beneath an emergency use programme, and a Chinese language well being official mentioned on Oct. 20 that severe negative effects haven’t been noticed in scientific trials.
(Reporting by Pedro Fonseca, Marcelo Rochabrun and Stephen Eisenhammer; Further reporting by Miyoung Kim and Roxanne Liu; Modifying by Edwina Gibbs)
((firstname.lastname@example.org; +55 11 5644 7768;))
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.